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Magnetic resonance imaging (MRI) is an imaging technique used primarily in 
medical settings to produce high quality images of the inside of the human body. Iron 
oxides (IOs) which increase the R2 relaxation rate of the surrounding medium to 
create signal voids on MR images, have been used as an MRI contrast agent. Their 
major applications include imaging of the liver, spleen, and breast. For future 
applications such as imaging of specific molecular targets to allow for earlier 
recognition and characterization of disease, earlier and direct evaluation of treatment 
outcomes, and a deeper understanding of disease development, there is a need to 
develop special contrast agents with greater ability to amplify the MRI signals [1]. 
This can only be achieved if contrast agents are accumulated in the target cells by 
passive endocytosis, or by active transporter systems such as transferring receptors 
that shuttle contrast agents into targeted cells [2]. A feasible way of enabling active 
targeting is to employ a nanoparticulate structure, which can serve as a scaffold for 
targeting ligands and magnetic labels [3]. Therefore, much attention has been paid to 
the research and development of nanoparticles to further enhance the contrast 
efficiency of IOs.  
 
The main objective of this project is to develop a novel formulation of MR contrast 
agent by encapsulating IOs with biodegradable polymer, methoxy poly(ethylene 
glycol)-poly(lactide-co-glycolide) (PLGA-mPEG). The IOs used are commercial MR 
contrast agent Resovist®. The IO loaded PLGA-mPEG nanoparticles, prepared by 
 v
water in oil in water (w/o/w) double emulsion technique, were characterized by 
several techniques including laser light scattering (LLS) for the particle size, field 
emission scanning electron microscopy (FESEM) for the surface morphology, 
transmission electron microscopy (TEM) for qualitative determination of IOs loaded, 
inductively coupled plasma-optical emission spectroscopy (ICP-OES) and/or 
inductively coupled plasma-mass spectrometer (ICP-MS) for quantitative 
determination of IOs loaded, superconducting quantum interference device (SQUID) 
for magnetization measurement, and MRI for contrast effect determination. In 
addition, in vitro release study to determine the release kinetics profile and stability 
tests to evaluate the resistance of the IO loaded PLGA-mPEG nanoparticles towards 
aggregation and iron leakage upon exposure to osmotic agent NaCl (sodium chloride) 
were carried out.   
 
These nanoparticles were spherical with an average diameter of 233.0 nm and a 
relatively narrow size distribution of ±12.5 nm. The iron loading was 1.37%. They 
showed enhanced saturation magnetization, improved r2 and r2* relaxivities, and 
increased contrast effect of both in vitro and ex vivo MR images. The feasibility of 
the enhancement effect achieved can be substantiated by MR theories such as 
motional averaging regime (MAR) and static dephasing regime (SDR). The signal 




In summary, the remarkable increase in the MR contrast efficiency of the developed 
IO loaded PLGA-mPEG nanoparticles over the commercial IO contrast agent 
Resovist®, suggests that these nanoparticles could be potential MRI contrast agent.  
 vii
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Magnetic resonance imaging (MRI) is a popular non-invasive method for clinical 
diagnosis of soft tissue or cartilage pathologies with new ideas of considerable 
potential surfacing on a regular basis [4]. It produces image contrast based on the 
different relaxation times of hydrogen nuclei, provides great technical flexibility, and 
is free of the hazards related to ionizing radiation. 
 
It is well known that the presence of magnetic particles within tissue allows a very 
large MRI signal to be obtained. The MRI signal is affected by the interaction of the 
total water signal (proton density) and the magnetic properties (R1 [the longitudinal 
relaxation rate (1/s)] and R2 [the transverse relaxation rate ([(1/s)]) of the tissues 
being imaged. The most frequently used nonspecific contrast agents are gadolinium-
based. Their paramagnetism manipulates R1 of the surrounding molecules to increase 
the total signal. In recent years, superparamagnetic iron oxides (SPIOs) that enhance 
R2 of the surrounding medium to produce signal voids on magnetic resonance images 
have been developed [4]. 
 
Iron oxides (IOs) are the most-studied materials for magnetic targeting because of 
their favorable magnetic properties and high biocompatibility. Superparamagnetic 
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 magnetite and maghemite have the highest saturation magnetizations (Ms) among the 
IOs [5]. SPIO contrast agents are small synthetic γ-Fe2O3 or Fe3O4 particles with a 
core size of less than 10 nm and an organic or inorganic coating. They have no 
remnant magnetic moment once the external field is withdrawn.  
 
The suitability of the IOs as a contrast agent for MRI depends upon: 
a) Their magnetic susceptibility to achieve magnetic enhancement [6]; 
b) Their sizes should ideally be in the range of 6-15 nm [7]; 
c) The exhibition of their superparamagnetic characteristics [8]; 
d) Customized surface chemistry for precise biomedical applications [9]. 
 
The efficacy of IOs as MR contrast agent can be assessed through their abilities to 
alter the relaxation rates. The MR properties of the IOs were characterized and 
quantified by relaxivity, which is defined by 
 0R R r C= + ⋅                                                            (1.1) 
where R is the proton relaxation rate (1/T, s-1) in the presence of the contrast agent, R0 
is the relaxation rate in the absence of the contrast agent and C is the contrast agent 
concentration (mM). The constant of proportionality, r is the T-relaxivity ( 1 1mM s− −⋅ ) 
[10].  
 
Two main factors that influence the relaxation rates are the magnetization of the IOs 
and the diffusion of the water molecules in the surrounding medium. The 
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 magnetization of the IOs is directly correlated to its size. In other words, the larger 
the particle size of the IOs, the stronger the magnetization. The diffusion time Dτ  is 
the time during which the protons of the water molecules experience the magnetic 
field of the IOs and is given by  where rDrpD /
2=τ p is the radius of the IOs and D is 
the diffusion coefficient.  
 
Depending on the rate of diffusion of the water molecules and size of IOs, they can be 
operating in the motional averaging regime (MAR) or static dephasing regime (SDR). 
In both regimes, the R2 relaxation rate (measured using single (Hahn) spin-echo 
sequence) is considered to be equal to R2* relaxation rate (measured using gradient 
echo sequence) because the time to echo (TE) is too long for the 180° refocusing 
pulse in the spin-echo sequence to be effective. Briefly speaking, when the radius of 
the IOs is small and the diffusion time taken for the water molecules to diffuse a 
distance of pr2 in any specified direction is short, the IOs are said to be in the MAR. 
In this regime, relaxation rates increase linearly with particle size. When the IOs are 
large enough, it can be assumed that the diffusion time is so long that the water 
molecules are effectively motionless and the IOs are in the SDR. In this regime, the 
maximum relaxation rates are achieved. However, we should note that in situations 
where R2 ≠ R2* and IOs are very large, R2 relaxation rate actually decreases as particle 
size increases. 
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 Presently, a range of SPIO contrast agents have been developed, with variations in 
hydrodynamic particle sizes (from 10 to 500 nm) and coating materials used (such as 
dextran, starch, albumin, silicones, poly(ethyleneglycol)). Some of them have been 
approved for clinical use and are marketed under the trade names such as Lumirem®, 
Endorem®, Sinerem® and Resovist®. Their major applications include imaging of 
the liver, spleen, and breast. For future applications such as imaging of specific 
molecular targets to allow for earlier recognition and characterization of disease, 
earlier and direct evaluation of treatment outcomes, and a deeper understanding of 
disease development, there is a need to develop special contrast agents with greater 
ability to amplify the MRI signals [1]. Significant signal amplification can be 
achieved if the contrast agent is allowed to accumulate in the target cells by passive 
endocytosis, or by an active transporter system such as a transferring receptor that 
shuttles targeted contrast agent into the cell [2]. In order to do so, the current IOs have 
been improved to enable active targeting. A feasible way of doing so is to employ a 
nanoparticulate or complex macromolecular structure such as liposomes and 
dendrimers. In general, nanoparticulates offer large surface area, which can serve as a 
scaffold for targeting ligands and magnetic labels [3]. Therefore, much attention has 
been paid to the research and development of IO encapsulated nanoparticles.   
 
IO loaded nanoparticles made from biocompatible and biodegradable polymers such 
as poly D,L lactide (PLA), poly(D,L latide-co-glycolide) (PLGA), 
poly(styrene/acetoacetoxyethyl methacrylate) (PS-AAEM) and polystyrene were 
reported in the literature [11, 12, 13, 14, 15, 16, 17]. These works had already 
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 addressed issues such as cytotoxicity, the influence of physicochemical properties 
(e.g. size and surface morphology), chemical composition of polymer matrix and iron 
entrapment efficiency, and conduct magnetization measurements. The magnetization 
values of the nanoparticles are important but not a direct indicator of efficacy of these 
nanoparticles as MRI contrast agents. So far, none of the research groups have carried 
out MRI measurements to determine the relaxivities of the IO loaded biocompatible 
and biodegradable polymeric nanoparticles developed. Though Pouliquen et al [18] 
carried out a very comprehensive study which included in vitro and in vivo MRI 
measurements, the magnetization measurements had not been conducted yet. In 
addition, their developed composite particles were in the micron range and produced 




As part of a programme to develop multi-functional nanoparticles that enable 
controlled and targeted MRI for diagnostic and therapeutic purposes, we would like 
to produce composite particles in the nano range that can increase the MR 
relaxivities.  The main objective of this project is thus to develop a novel formulation 
of MR contrast agent by encapsulating IOs with biodegradable polymer, methoxy 
poly(ethylene glycol)-poly(lactide-co-glycolide) (PLGA-mPEG). Our studies were 
conducted with comparison to commercially available IOs (Resovist®). 
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 Complete characterizations of the IO encapsulated polymeric nanoparticles are 
required to determine whether they are suitable for MRI applications. Their 
physicochemical and magnetization properties were first characterized. The IO loaded 
PLGA-mPEG nanoparticles, prepared by water in oil in water (w/o/w) double 
emulsion technique, were characterized using several techniques including laser light 
scattering (LLS) for evaluating the particle size, field emission scanning electron 
microscopy (FESEM) for measuring the surface morphology, transmission electron 
microscopy (TEM) for qualitative determination of IOs loaded, inductively coupled 
plasma-optical emission spectroscopy (ICP-OES) and/or inductively coupled plasma-
mass spectrometer (ICP-MS) for quantitative determination of IOs loaded, and 
superconducting quantum interference device (SQUID) for magnetization 
measurements. In addition, in vitro release study to determine the release kinetics 
profile and stability tests to evaluate the resistance of the IO loaded PLGA-mPEG 
nanoparticles towards aggregation and iron leakage upon exposure to osmotic agent 
sodium chloride (NaCl) were also carried out.  
 
To assess the efficacy of IO loaded PLGA-mPEG nanoparticles as MRI contrast 
agents, in vitro MRI was first conducted to measure relaxation properties of both the 
IOs and IO loaded PLGA-mPEG nanoparticles. After which, ex vivo MRI studies 
were carried out by imaging the organs of rats injected with IO loaded PLGA-mPEG 
nanoparticles. Biodistribution of IO loaded PLGA-mPEG nanoparticles in rats were 
studied as well. 
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 1.3 Organization of thesis 
 
The thesis consists of (i) thorough literature review; (ii) description of materials and 
methods used in the novel formulation of biodegradable IO loaded PLGA-mPEG 
nanoparticles; (iii) results and discussions of their physicochemical characterization; 
(iv) magnetization properties and MRI studies; and (v) conclusion and 
recommendations. The literature review covers the basics of biodegradable polymers, 
their manufacture techniques, the working principle behind MRI, its contrast agents, 
and previous work done on IO encapsulated polymeric nanoparticles. Under the 
materials and methods section, detailed descriptions of materials and methods used in 
the preparation of biodegradable IO loaded PLGA-mPEG nanoparticles are given. 
The results of the characterization experiments, magnetization measurements, in vitro 
MRI and animal studies are presented and discussed in four separate chapters. In the 
concluding section, the results are summarized, and some suggestions for future 









 Chapter 2 Literature Review 
 
2.1 Nanoparticles of Biodegradable Polymers  
 
2.1.1 Basic information of Biodegradable Polymers 
 
Recently, there has been increased interest in developing long-circulating 
nanoparticles as a drug carrier. The studies using polymeric biodegradable 
nanoparticles to encapsulate anti-tumor drugs such as paclitaxel, doxorubicin and 5-
fluoruracil have demonstrated promising results for the treatment of cancer in animal 
models. Besides being a potential drug delivery system, nanoparticles can be used for 
fluorescent biological labels, gene delivery, separation and purification of biological 
molecules and cells, MRI contrast enhancement, and detection of proteins [19]. 
Furthermore multi-functional nanoparticles can also be developed to encapsulate both 
drug and MRI contrast agent to achieve simultaneous diagnostic and therapeutic 
effects. 
  
One of the factors determining the particle size and the size distribution of 
nanoparticles is the preparation methods used such as solvent extraction/evaporation 
and spontaneous emulsification/solvent diffusion. Nanoparticles manufactured using 
solvent evaporation tend to be larger (300 nm and above) while those prepared using 
solvent diffusion can be made to be smaller than 100 nm. Nanoparticles can also be 
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 prepared by polymerization of monomers. Hydrophilic nanoparticles with diameters 
less than 100 nm and narrow size distribution have been prepared by using the 
aqueous core of the reverse micellar droplets as nanoreactors [20]. 
 
An advantage of nanoparticles is that due to their small sizes, they can pass through 
smaller capillaries and be taken up by cells, thereby allowing efficient drug and/or 
IOs accumulation at the target sites. Also, being made of biodegradable materials, 
they can achieve sustained drug release at the target site. Nanoparticles may offer 
protection to the drug molecules during transportation in the circulation and 
nanoparticle formulation can be developed into a platform technology applicable to a 
wide range of drugs, either hydrophilic or lipophilic. Drugs and/or IOs may be bound 
to nanoparticles in various forms, such as a solid solution, dispersed or adsorbed on 
the surface or chemically attached. The surface of nanoparticles can be modified to 
prolong their blood circulation and coated or attached with targeting ligands to 
achieve site-specific drug delivery. However, nanoparticles tend to be removed 
rapidly from the blood circulation following intravenous administration. The rate of 
nanoparticle removal is related to both particle size and surface characteristics. 
Ideally, the size of the long-circulating rigid particles should not exceed 200 nm, 
preferably in the range of 120-200 nm in diameter, in order to decrease clearance by 
the reticuloendothelial system (RES). Nanoparticles used for drug delivery to the 
brain are generally the diameters of 60 – 400 nm. Efforts have been made to modify 
the surface of nanoparticles to increase their systemic circulation time, by either 
physical adsorption of a hydrophilic polymer on the particle surface or chemical 
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 grafting of polymer chains onto particles. To date, the most successful long-
circulating biologically stable nanoparticles have been coated with PEG [21].  
 
2.1.2 Manufacture techniques of nanoparticles 
 
There are many ways to manufacture the nanoparticles, for instance, dispersion of the 
preformed polymers or by polymerization of monomers [20]. Some other more 
commonly used methods are briefly described in this section. 
 
Solvent extraction/evaporation
In the solvent extraction/evaporation technique, the polymer is dissolved in an 
organic solvent such as dichloromethane, chloroform or ethyl acetate. The 
hydrophobic anticancer drug is dissolved or dispersed into the preformed polymer 
solution, and the resulting mixture, after emulsification by high-speed 
homogenization or sonication, is added into an aqueous solution to make an oil-in-
water emulsion with the aid of an amphiphilic surfactant emulsifier/stabilizer/additive 
(single emulsification). If the anticancer drug is hydrophilic, the technique is slightly 
modified to form a water-in-oil-in-water (w/o/w) emulsion (double emulsification) 
[22]. After the formation of a stable emulsion, the organic solvent is evaporated by 
continuous stirring in an increased temperature or a decreased pressure (vacuum) 
environment, with or without the aid of an inertial gas flow. Centrifugation or 
filtration is applied to collect the formed particles, which can then be freeze-dried to 
 10




Technologies such as spray-dry and spray-freeze-dry have been developed for mass 
production of drug-loaded nanoparticles. In brief, the drugs are suspended or 
dissolved in organic solution where the polymer is also dissolved, and then the 
mixture is spray dried to form particles. The challenges for spray-drying include how 
to produce particles with sufficiently small size and how to increase the drug 
encapsulation efficiency [23]. 
 
Spontaneous emulsification/solvent diffusion 
This technique, in which a water-soluble solvent (e.g., acetone or methanol) and a 
water-insoluble organic solvent (e.g., dichloromethane or chloroform) are used, 
employs low-energy emulsification [24]. Due to the spontaneous diffusion of the 
water-soluble solvent, an interfacial turbulent flow is created between the two phases, 
leading to the formation of nanoparticles. As the concentration of water-soluble 
solvent increases, a considerable decrease in particle size can be achieved [25]. 
 
Supercritical fluid spraying
Production of polymeric nanoparticles by supercritical fluid spraying does not 
required the use of any toxic organic solvent and surfactant. The drug and the 
polymer of interest are solubilized in a supercritical fluid, and the solution is 
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 expanded through a nozzle. The supercritical fluid is evaporated in the spraying 
process and the solute particles eventually precipitate. This technique is clean because 
the precipitated solute is completely solvent-free [26].  
 
Polymerization of monomers 
Polymerization includes emulsion polymerization and interfacial polymerization. 
Emulsion polymerization builds up a chain of polymers from single monomers. When 
the monomer-contained organic phase and aqueous phase are brought together by 
mechanical force, interfacial polymerization will take place. Couvreur et al  [27] 
reported the production of nanoparticles of about 200 nm diameter by polymerizing 
mechanically the dispersed methyl or ethyl cyanoacrylate in aqueous acidic medium 
in the presence of polysorbate-20 as a surfactant. The cyanoacrylic monomer is added 
to an aqueous solution of the surface-active agent under vigorous mechanical stirring 
to polymerize alkylcyanoacrylate at ambient temperature. The drug is dissolved in the 
polymerization medium either before the addition of the monomer or at the end of the 
polymerization reaction. The nanoparticle suspension is then purified by 
ultracentrifugation or by resuspending the particles in an isotonic medium. During 
polymerization, various stabilizers such as dextran and poloxamer are added. In 





 2.2 Introduction to MRI 
 
MRI is an imaging technique that generates images of the body using nuclear 
magnetic resonance (NMR). When a patient is placed into the cylindrical magnet, a 
magnetic steady state is first created within the body by using a strong magnetic field. 
Then the body is stimulated with radio waves to change the steady-state orientation of 
protons and the electromagnetic signals emitted from the body is used to construct 
detailed internal images of the body using a computer program. This technique is 
non-invasive, and free of the hazards associated with ionizing radiation. 
 
2.2.1 Basic principles of MRI 
 
Nuclear spin is the basis of NMR. When a nucleus contains an even number of 
protons and neutrons, the individual spins of these particles pair off and cancel out, 
leaving the nucleus with zero spin. However, if a nucleus has an odd number of 
protons or neutrons, there is incomplete pairing and the net spin is ½. All such nuclei 
experience NMR, but in clinical MRI the hydrogen nucleus, comprising of a single 
proton, is used because of its high NMR sensitivity and its natural abundance in the 
human body.  
  
For clinical applications, a powerful magnet is used to provide a strong uniform 
constant ‘longitudinal’ magnetic field (B0) in the z-direction. Its magnetic field 
strength is typically 4000 to 60 000 times that of the Earth. It generates a macroscopic 
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 magnetisation due to alignment of hydrogen nuclei with the field. However, to obtain 
MR images, an external magnetic field has to be applied to excite the hydrogen 
nuclei. The radio frequency (RF) coils are used to transmit RF pulses required for 
excitation, and also to detect the emitted MR signal which is known as free induction 
decay (FID). Following excitation, the nuclei return to their equilibrium state either 
through the loss of energy from the spin system or simply exchange of energy 
between spins. These two types of relaxation processes are known as spin–lattice and 
spin–spin relaxation, and are characterized by the relaxation times T1 and T2, 
respectively. The MRI signal is thus the product of interaction between the total water 
signal (proton density) and the magnetic properties (1/T1 [the longitudinal relaxation 
rate (1/s)] and 1/T2 [the transverse relaxation rate [(1/s)]) of the tissues being imaged.  
 
2.2.2 T1 process 
 
At equilibrium, the net magnetization vector lies along the direction of the applied 
magnetic field Bo and is called the equilibrium magnetization M0. In this case, the 
longitudinal magnetization MZ equals M0 and there is no transverse (MXY) 
magnetization. The time constant which describes how MZ returns to its equilibrium 
value is called the spin-lattice relaxation time (T1). The equation governing this 










2.2.3 T2 process 
 
The time constant which describes the return to equilibrium of the transverse 
magnetization, MXY, is called the spin-spin relaxation time, T2. It is given by: 




T2 is always less than or equal to T1. The net magnetization in the XY plane goes to 
zero and then the longitudinal magnetization grows until we have M0 along Z. The 
two factors that contribute to the decay of transverse magnetization are molecular 
interactions (pure T2 molecular effect) and spatial variations in B0 (inhomogeneous T2 
effect) within the body. The combination of these two factors is what actually results 
in the decay of transverse magnetization. The combined time constant is called T2* 
and is given as follows.  
       oinTTT hom222 /1/1*/1 +=                                       (2.3) 
 
2.2.4 Imaging Techniques 
 
In this project, the single (Hahn) spin-echo sequence and the gradient echo sequence 
are used to obtain the R2 (=1/T2) and R2* (=1/T2*) relaxation rates, respectively. The 
spins are refocused to compensate for local magnetic field inhomogeneities in T2 
imaging, but not in T2* imaging. This sacrifices some image resolution but provides 
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 additional sensitivity to the relaxation processes that cause incoherence of transverse 
magnetization. 
 
Spin-echo Sequence  
The time between repetitions, is called the repetition time (TR), of the sequence. The 
TE defined as the time between the 90o pulse and the maximum amplitude in the 
echo. In brief, the spin-echo sequence begins with a 90o pulse and produces a FID that 
decays according to the T2* relaxation time. After a delay time of TE/2, a 180o 
refocusing pulse is applied to invert the spins, it reestablishes phase coherence and 
generates an echo at TE. The inhomogeneities of external magnetic field are cancelled 
and the peak amplitude of the echo is determined by T2 decay.  
 
Gradient echo sequence
Unlike the spin-echo sequence, it does not have a 180o refocusing pulse. The spins are 
refocused by reversing the direction of the spins rather than flipping them over to the 
other side of the XY plane. Gradient refocusing of the spins takes considerably less 
time than 180 o RF pulse refocusing. The disadvantage of gradient echo sequences is 
the loss of signal due to magnetic field inhomogeneity.  
 
2.3  Introduction to MRI contrast agent 
 
2.3.1 Types of contrast agents 
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 The most commonly used contrast agents are gadolinium-based. Their paramagnetism 
changes the R1 relaxation rate of the surrounding molecules to give an increase in 
total signal. In recent times, iron oxides were developed as MR contrast agents. They 
work by enhancing the R2 relaxation rate of the surrounding medium to reduce signal 
intensity on MR images.  
 
 
2.3.2 Classification of IOs 
 
To date a wide variety of IOs have been produced, differing in particle sizes 
(hydrodynamic particle size varying from 10 to 500 nm) and types of coating 
materials used (such as dextran, starch, albumin, silicones, poly(ethyleneglycol)). 
They tend to be classified into two main groups according to their size, as this affects 
plasma half-life and biodistribution. The first group are termed superparamagnetic 
iron oxides (SPIOs) where nanoparticles have a size greater than 50 nm (coating 
included) and the second type termed ultrasmall superparamagnetic iron oxides 
(USPIOs) where nanoparticles are smaller than 50 nm. Both types of particles are 
commercially available. Some examples of SPIOs are Lumirem®, silicon-coated 
particles with 300 nm diameter, and Endorem®, magnetite particles with a 150 nm 
diameter. They are used for gastro-intestinal tract imaging and for liver and spleen 
disease detection, respectively. The USPIOs can act as blood pool agents for 
perfusion imaging of brain or myocardial ischemic diseases. For example, Sinerem®, 
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 which is currently being used for tumour detection, consists of magnetite particles 
with a 30 nm diameter [28]. 
 
The particle size also affects the relaxation rates of IOs. USPIO can be considered as 
a single ferrite crystal, so a uniform distribution of the magnetic crystals within the 
solvent can be assumed for the calculation of its nuclear magnetic relaxation rate [29, 
30, 31]. However, for SPIO which contain several ferrite crystals per particle, this 
assumption is no longer valid. The transverse relaxation is affected by the 
agglomeration and determined by two components. The first is the SPIO crystal itself 
and the second is the assumption of the entire particle as one large sphere [32].  
 
2.3.3 Relaxation rates of IOs 
 
The two main factors that influence the relaxation rates are the magnetization of the 
IOs and the diffusion of the water molecules in the surrounding medium. Depending 
on the rate of diffusion of the water molecules and the size of IOs, they can be 
operating in the MAR or SDR.  
 
MAR 
In the MAR, the relaxation rate can be obtained from the quantum mechanical outer 
sphere theory:  
2
2 )()9/4( rDvR ωτ ∆=                                                     (2.4) 
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 where v is the volume fraction occupied by the magnetized spheres, Dτ  is the 




4 3 MrB peqr γπγµγω ===∆  where γ is the proton 
gyromagnetic ratio, is the equatorial magnetic field of the particle, eqB µ is its 
magnetic moment and M is its magnetization. Equation (2.4) is valid if the particles 
are small enough to satisfy the motional averaging condition ( 1<∆ Drτω ), and 
relaxation is not affected by the refocusing echo pulse [33]. In this regime, the 
relaxation rate increases linearly with particle size and R2 = R2*.  
 
SDR 
In the SDR, there is dephasing of motionless magnetic moments of the protons by the 
randomly distributed IOs in a non-uniform field. There exists an upper limit on the R2 
relaxation rate that can be reached in the absence of a refocusing pulse and R2 = R2*. 
This limit is given by:  
9/15*2 rvR ωπ ∆=                                                       (2.5) 
Though equation (2.5) is formulated based on the assumption of motionless spins, it 
remains valid for slow motion as long as the particles are large enough to satisfy the 
condition 1>∆ Drτω [34, 35].  
 
However, we should note that these two regimes are applicable only for cases where 
the 180° refocusing pulse used in the spin echo sequence is not effective to recover 
signal loss due to field inhomogeneities, thus R2 = R2*. In situations where R 2 ≠ R2* 
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 and the particles are very large, the R 2 relaxation rate actually decreases as particle 
size increases [36].  
PRESS 
2.4 Research done on IO encapsulated polymeric nanoparticles 
 
Ideally, these polymeric magnetic carriers should be small enough (less than 1µm) to 
pass through capillaries to reach the targeted site, have adequate magnetic sensitivity 
to magnetic fields in physiological environments, evoke minimum toxicity and 
immunological response, and be also biodegradable with no or little toxicity of 
degradation products [37]. Some of the popular biocompatible and biodegradable 
polymers researched on are poly(D,L latide-co-glycolide ) (PLGA), poly(D,L lactide) 
(PLA), and poly(glycolide) (PGA) [38, 39, 40]. A considerable amount of work has 
also been done to demonstrate that biodegradable polymers are ideal as carriers 
because of their minimum toxicity and immunological response [41, 42, 43, 44]. The 
combination of biocompatible and biodegradable polymer with SPIOs enables the 
minimization of systemic side effects while sustaining local higher concentrations of 
the contrast agent [45]. 
 
Several researchers have described the methods on how to prepare these IO loaded 
nanoparticles of biodegradable polymers. Muller et al [11] produced magnetite loaded 
PLA and PLGA nanoparticles, sizes of which were between 456 and 890 nm with a 
theoretical magnetite content up to 50% (w/w). These magnetite loaded polymeric 
nanoparticles have relatively low cytotoxicity, qualifying them as potential 
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 formulation for intravenous injection. Okassa et al [12] achieved the incorporation of 
modified magnetite/maghemite nanoparticles into PLGA nanoparticulate matrix, but 
did not report any magnetization properties of these composite nanoparticles. Gomez-
Lopera et al [13] also synthesized composite particles by coating a magnetic nucleus 
(magnetite) with a biodegradable PLA polymer, but they found these composite 
particles had decreased saturation magnetism. Lee et al. [14] prepared ferrofluidic 
PLGA nanoparticles and suggested that a decrease in particle size may increase the 
magnetic susceptibility of nanoparticles as a result of the increase in packing density 
or volume fraction of the nanoparticles. They also reported MRI image enhancement 
in the kidney of rabbit after injection of their composite nanoparticles. Other 
polymers were also used to encapsulate IOs. Dresco et al. [15] synthesized magnetite 
and polymer magnetite nanoparticles using methacrylic acid and hydroxyethyl 
methacrylate, but they assumed that the magnetic susceptibility of magnetite did not 
change after the encapsulation into the polymer matrix. Pich et al. [16] prepared 
composite poly(styrene/acetoacetoxyethyl methacrylate) (PS-AAEM) particles with 
encapsulated magnetic IO, and Zheng et al  [17] incorporated up to 40 % (w/w) of 8 
nm superparamagnetic magnetite particles into polystyrene nanospheres with an 
average diameter of 80 nm. These works had addressed issues of cytotoxicity, 
investigated the influence of physicochemical properties such as size and surface 
morphology, chemical composition of polymer matrix and iron entrapment 
efficiency, and conducted magnetization measurements. The magnetization values of 
the nanoparticles are important but not a direct indication of efficacy of these 
nanoparticles as MRI contrast agents. So far, none of the research groups have carried 
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 out MRI measurements to determine the relaxivities of the IO loaded biocompatible 
and biodegradable polymeric nanoparticles they developed. Though Pouliquen et al 
[18] had carried out a very comprehensive study which included in vitro and in vivo 
MRI measurements; they did not carried out magnetization measurements. In 
addition, their developed composite particles were in the micron-range and produced 
decreased MR relaxivities.  
 
Encapsulation of SPIOs with biodegradable polymers allows surface modification of 
the nanoparticles to prolong their blood circulation, and coating or attachment of 
targeting ligands leads to achieving site-specific drug delivery. Long circulating 
nanoparticles can be obtained by coating with polyethene glycol (PEG). Drugs 
encapsulated in these nanoparticles have been shown to passively target the tumour 
tissue through enhanced permeability and retention (EPR) effect [46, 47]. Cell-
specific targeting of contrast agents allows early MRI detection of tumour cells. For 
potential active targeting through surface modification, much research had been 
conducted on targeted drug delivery through the attachment of ligands such as folic 
acid [48] and lectins [49] which are over expressed in certain tumour cells. The 
coating of the particle surface may also help nanoparticles to cross physiological 
barriers. One such example is the use of polysorbates to coat 
poly(butylcyanoacrylate) nanoparticles to enhance their drug delivery cross the blood 








Resovist®, a commercial MRI contrast agent, was purchased from Schering AG for 
used as IOs in this project. It is a stable, aqueous solution of SPIOs coated with 
carboxydextran in an approximate ratio of 1:1.1 (w/w). The PLGA-mPEG polymer 
with 4.75 % (w/w) PEG and lactide:glycolide molar ratio of  80:20 was a kind gift 
from Curtin University of Technology, Australia. The PEG polymer has molecular 
weight (MW) of 2,000 Da while the PLGA polymer has MW of 30,000 - 50,000 Da, 
Polyvinyl alcohol (PVA) with MW of 30,000~70,000 was purchased from Sigma-
Aldrich Co., USA. Milli-Q water with resistivity of 18.2 MΩ•cm was obtained from a 
Milli-Q Plus System (Millipore Corporation, Breford, USA). Dichloromethane 
(DCM) was purchased from Merck & Co., Inc.,USA, concentrated (>69.5%) nitric 
acid was from Sigma-Aldrich Co., USA, and 31.0% hydrogen peroxide was from 
Kanto Corporation, USA. 
 
3.2 Preparation of the nanoparticles 
 
The IO loaded PLGA-mPEG nanoparticles were prepared by w/o/w double emulsion 
technique as shown in Figure 3.1. Briefly, 0.17 ml of IO aqueous suspension was 
added to 2.5 ml of 2% PLGA-mPEG DCM solution and sonicated using a 
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 MICROSONICTM ultrasonicator equipped with a microtip probe (XL2000, Misonix 
Incorporated, NY) for 60s at 25W, to obtain an water-in-oil emulsion. Then, this 
water-in-oil emulsion was poured into an aqueous PVA (as an emulsifier) solution 
(1% (w/v)) and sonicated for 90s at the same energy output. The organic solvent was 
rapidly removed by evaporation under mechanical stirring at room temperature 
overnight (for 12h). The formed nanoparticles were collected by centrifugation 
(Eppendorf 5810R) at 12,000 rpm for 15min at 20◦C and washed with Milli-Q water 
for three times to remove excessive emulsifier and free IOs. To obtain fine powder of 
nanoparticles, nanoparticle suspension was freeze dried using a freeze dryer (Christ, 
Alpha-2, Martin Christ, Germany). Nanoparticle suspension was used for all 
characterization work. Blank PLGA-mPEG nanoparticles were prepared in the same 
way by replacing the IO aqueous suspension with water. 
 
Figure 3.1 Schematic of the preparation of IO loaded PLGA-mPEG 






 3.3 Physicochemical characterization of the nanoparticles 
 
3.3.1 XRD Analysis 
 
Crystallographic analysis of the IOs was performed by XRD machine (Bruker, 
Advance D8, USA) with a Cu kα radiation (λ=1.54056 Å) to identify the dominant 
phase of the IOs in order to estimate the maximum theoretical relaxation rate that the 
IOs can achieve. The phase was determined using standard powder diffraction files of 
Joint Committee for Powder Diffraction Studies (JCPDS). 
 
3.3.2 Surface chemistry 
 
X-ray photoelectron spectroscope (XPS, AXIS His-165 Ultra, Kratos Analytical, 
Shimadzu, Japan) was used to determine the surface chemistry of the IOs. Curve 
fitting of the experimental data was performed using the software supplied by the 
manufacturer. 
 
3.3.3 Particle Size analysis 
 
The particle size and size distribution of the prepared IO loaded PLGA-mPEG 
nanoparticles were determined by LLS with a particle size analyzer (90 Plus, 
Brookhaven Inst, Huntsville, US) at a fixed angle of 90◦ at 25◦C. In brief, the 
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 nanoparticles were suspended in Milli-Q water and sonicated to produce homogenous 
suspension of nanoparticles. 
 
3.3.4 Surface morphology 
 
The surface morphology of the IO loaded PLGA-mPEG nanoparticles was observed 
by FESEM (JSM-6700F, JEOL, Japan) at an accelerating voltage of 10 kV after 
platinum coating of the nanoparticles by a sputter coater (JFC-1300, JEOL, Tokyo, 
Japan) for 30 s in a vacuum at a current intensity of 30 mA. The nanoparticles were 
immobilized on metallic studs with double-sided conductive tape. 
 
3.3.5 TEM Measurement 
 
TEM (JEM 2010F, JEOL, Japan) examination of the IOs and IO loaded PLGA-
mPEG nanoparticles was carried out with an electron kinetic energy of 200kV. A 
drop of well dispersed nanoparticle aqueous suspension was placed on a 
Formvar/carbon 200 mesh copper grid and then dried at ambient condition before it 
was attached to the sample holder on the microscope. 
 
3.3.6 ICP-MS and ICP-OES measurements 
 
The iron contents of both IOs and IO loaded PLGA-mPEG nanoparticles were 
determined by either ICP-MS (Elan 6100, Perkin-Elmer, USA) or ICP-OES (Optima 
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 3000DV, Perkin-Elmer). For iron concentrations in dilute solutions (less than 10 parts 
per million), the ICP-MS was used. In solutions with higher iron concentrations 
(more than 10 parts per million), the ICP-OES was employed. To completely digest 
the samples to release iron before ICP-MS or ICP-OES analysis, the particles were 
pre-treated using microwave digestion system (1200 MEGA, Milestone, Leutkirch, 
Germany). In brief, 10mg particles, 3ml of Milli-Q water, 2ml of concentrated nitric 
acid and 1.5ml of 31.0% hydrogen peroxide were added to each digestion vessel and 
digestion was performed with the program developed by Krachler et al [54]. The 
amount of iron loading (% w/w) was calculated as the ratio of the mass of iron (mg) 
that can be detected using ICP analysis to the sum of the mass of iron (mg) and the 
mass of polymer (mg). 
 
3.3.7 Magnetic properties 
 
The saturation magnetization of the IOs and the IO loaded PLGA-mPEG 
nanoparticles was determined by vibrating sample magnetometer (VSM, Lakeshore 
7300 Series, US) and SQUID (MPMS XL5, Quantum Design, US). The temperature-
dependent magnetization of the samples was obtained by measuring the 
magnetization in the temperature range of 2-400K with maximum applied field of 20 
kOe. Blocking temperatures (TB) could be read from ZFC (zero field cooling) and FC 
(field cooling) curves taken under the applied magnetic field of 100Oe between 2 and 
400K. To obtain the ZFC graph, the samples were cooled from 400 K to 2 K without 
applying an external field. After reaching 2 K, a 100 Oe field was applied and the 
 27
 magnetization was recorded as the temperature increased. For measuring FC, the 
samples were first cooled from 400 K under an applied field of 100 Oe, and then the 
magnetization was recorded as the temperature increased. 
 
3.3.8 Stability study 
 
The IO loaded PLGA-mPEG nanoparticles were evaluated for their resistance to 
osmotic agent NaCl, which potentially may cause nanoparticle aggregation and iron 
leakage. 60 mg of the nanoparticles were added to 20ml of 0.9% (w/w) NaCl solution 
and incubated at 37◦C in a mildly shaking water bath. Particle size was measured after 
0, 18, 24 and 48h using LLS, and iron leakage was determined by measuring the 
amount of iron in the supernatant after 48h using ICP-MS. 
 
3.3.9 In vitro release study 
 
5 mg of the IO loaded PLGA-mPEG nanoparticles were placed in each centrifuge 
tube and then 10ml of fresh PBS (phosphorus buffered solution) at pH=7.4 was 
added. The tubes were put into a 37oC orbital shaker bath and shaken horizontally at 
120 times per minute. The tubes were removed from the shaker bath at pre-
determined time intervals and centrifuged at 10500 rpm at 18oC for 15 minutes. Then 
9 ml of the supernatant was collected for the release analysis. After that, 9 ml of fresh 
PBS was refilled into the tubes. The nanoparticle pellet was re-suspended in 10 ml 
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 PBS and returned to the shaker bath.  The amount of iron released from the IO loaded 
PLGA-mPEG nanoparticles was measured using ICP-MS. 
 
3.4 MR Characterization of the nanoparticles 
 
3.4.1 In vitro MR Imaging 
In vitro r1, r2 and r2* relaxivities of the IOs and the IO loaded PLGA-mPEG 
nanoparticles suspended in water were measured. MR images of the nanoparticles 
were obtained using a Siemens Symphony 1.5 Tesla scanner with a head coil. MR 
imaging was carried out with different concentrations of the IOs and the IO loaded 
PLGA-mPEG nanoparticles from 0 mM to 0.5 mM. The spin echo sequence was 
used. The imaging parameters are flip angle = 90○, number of excitations (NEX) = 1, 
field of view (FOV) = 180mm and slice thickness = 5mm. The values for TR and TE 
of the IOs and the IO-loaded PLGA-mPEG nanoparticles to obtain r1, r2 and r2* 
relaxivities were given in Table 3.1.  
 
Table 3.1 The TE and TR parameters for measuring relaxivities of the IOs and 
IO loaded PLGA-mPEG nanoparticles. 
 r1 r2 r2* 
IOs 25 ≤ TR≤ 200ms, 
TE = 9ms 
9 ≤ TE≤ 360 ms, 
TR = 2400 ms 




25 ≤ TR≤ 
6400ms,  
TE = 12ms 
20 ≤ TE≤ 160ms, 
TR = 1600 ms 
5 ≤ TE≤ 60ms, 
TR = 1600ms 
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 3.4.2 Ex vivo MR Imaging 
This study was performed according to a protocol conformed to the animal care 
legislation and approved by Institutional Animal Care and Use Committee (IACUC), 
National University of Singapore. 
 
Male Sprague Dawley rats (200~250 g) were used. An amount of IO loaded PLGA-
mPEG nanoparticles equivalent to 3.69 mg Fe/kg body weight was intravenously 
injected as an aqueous dispersion (0.922 mg Fe/ml) over 300 s into the rat under 
anaesthesia. Another rat injected with equivalent volume of saline was used as 
control. The rats were dissected and sacrificed under anaesthesia one hour after the 




Male Sprague Dawley rats (200~250 g) were used. An amount of IO loaded PLGA-
mPEG nanoparticles equivalent to 1.87 mg Fe/kg body weight was intravenously 
injected as an aqueous dispersion (1.87 mg Fe/ml) over 300 s into the rat under 
anaesthesia. An equivalent concentration of IOs was injected into another rat to be 
used as comparison. For control, saline was injected into the rat. One hour after the 
injection, the rat is sacrificed. The blood vessels are flushed with saline before the 
dissection. The rat was dissected to obtain the liver, spleen, kidney, and brain. After 
that, the removed organs are washed with saline and dried with gauze. The organs 
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 were then weighed to obtain the wet weight before freeze-drying. The dried organs 
were ground into powder, and weighed. Finally, 200mg of each type of organ powder 




 Chapter 4 Physicochemical Characterization  
 
In this project, Resovist®, a commercial MRI contrast agent, purchased from Schering 
AG, was used as the IOs to be encapsulated. According to the product phamplet, 1 ml 
of Resovist contained 28 mg of iron in the form of ferucarbotran. It was a stable, 
aqueous solution of SPIOs coated with carboxydextran in an approximate ratio of 
1:1.1 (w/w).  As the IOs play a significant role in influencing the properties of the IO 
loaded PLGA-mPEG nanoparticles, it is necessary to do a characterization study on 
them as well. The information gathered also served as a comparison when evaluating 
the IO loaded PLGA-mPEG nanoparticles.  
 
4.1 Crystalline structure and surface chemistry 
  
XRD result presented in Figure 4.1 identifies the IOs to be magnetite (Fe3O4) as all 
the major peaks correspond to the spinel Fe3O4 phase. Further investigation of XPS in 
the Fe 2p (atomic orbital 2p of iron) region confirms the presence of Fe2+ and Fe3+ 
ions, as shown by Peak 1 ( Fe3+) and Peak 2 ( Fe2+) in Figure 4.2 
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Figure 4.1 Peaks in XRD patterns of the IO correspond to spinel Fe3O4 phase 
peaks. 
 

















Figure 4.2 Fe 2p XPS of the IO showing Fe3+ and Fe2+ peaks. 
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 4.2 Size Distribution and Iron loading 
 
Factors, such as particle size and surface property of nanoparticles, could influence 
how long nanoparticles remain in circulation, how the nanoparticles interact with 
cells and their ability to penetrate drug barriers such as the BBB and gastrointestinal 
tract. TEM image presented in Figure 4.3(a) shows that the iron cores of the IOs (the 
dark dots) are very small, approximately 5 nm. According to the literature, the 
hydrodynamic size of Resovist® is approximately 60 nm [55]. The difference 
observed here is due to the dextran coating on the iron cores. We also used TEM to 
study encapsulation and location of IOs in nanoparticles. The TEM image in Figure 






Figure 4.3 TEM images of (a) the IOs (bar = 20 nm) and (b) the IO loaded 
PLGA-mPEG nanoparticles (bar = 50 nm). 
  
The hydrodynamic diameter and polydispersity of the nanoparticles can be obtained 
using LLS. Polydispersity is a quantitative measure of the uniformity of the 
nanoparticles. Generally, a uniform distribution is pursued. The amount of iron 
incorporated and average hydrodynamic size of both IOs and IO loaded PLGA-
mPEG nanoparticles were summarized in Table 4.1. The actual size distribution of 
the IO loaded nanoparticles was ±12.5 nm, as shown in Figure 4.4. As the size 
distribution was fairly narrow, the size of the IO loaded nanoparticles could be 
considered to be quite uniform. 
Table 4.1 Properties of the IOs and IO loaded PLGA-mPEG nanoparticles. 
Sample Fe content (%) Average hydrodynamic diameter (nm) 
IOs 22.02 ±2.31(n=5) 60 [35] 
IO loaded PLGA-mPEG 
nanoparticles 
1.37±0.02 (n=5) 233.0 
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IO loaded PLGA-mPEG nanoparticles
 
 
Figure 4.4 Particle size distribution of IO loaded PLGA-mPEG nanoparticles. 
 
4.3 Surface Morphology 
 
Surface morphology of IO loaded nanoparticles gives indication if any 
unencapsulated IOs present in the system as it may affect both magnetic property and 
release kinetics of IOs from the nanoparticles. FESEM image in Figure 4.5 shows that 
these nanoparticles are spherical and have relatively uniform size. No free IOs could 





Figure 4.5 FESEM images of the IO loaded PLGA-mPEG nanoparticles (bar = 1 
µm). 
 
4.4 Surface Charge 
 
Surface charge determines whether the nanoparticles will agglomerate in blood, their 
adhesion and interaction with the negatively charged cell membranes. It also affects 
the stability of the nanoparticles [56]. Surface charge is indicated by the zeta 
potential. The greater the zeta potential, the more stable the nanoparticles suspension 
will be because of the electrostatic repulsion. The zeta potential of the IO loaded 
PLGA-mPEG nanoparticles was negative as shown in Table 4.2. This can be 
attributed to the presence of ionized carboxyl groups and oxygen atoms of the ester 




 Table 4.2 Zeta potential of the IO loaded NPs 
Sample Zeta potential (mV)  




The stability of the IO loaded PLGA-mPEG nanoparticles was studied by measuring 
changes in the particle size and the level of iron leakage. There was no significant 
change (less than 5%) in the size of the nanoparticles when exposed to NaCl solution 
at 37◦C during the period of the study as seen in Figure 4.6. Therefore, it can be 
deduced that no aggregation had occurred in 48 hrs and the PLGA-mPEG 
nanoparticles were resistant to electrolytes. This stability of PLGA-mPEG 
nanoparticles is a result of the steric stabilization provided by mPEG molecules [58]. 
After 48 hours, the iron leakage was measured. Only 0.4% of the encapsulated IO 
leaked out. Thus, the formulations exhibited good stability in presence of 0.9% NaCl.. 
 38



















Time (h)  
Figure 4.6 Stability of 233 nm IO loaded PLGA-mPEG nanoparticles in NaCl 
solution at 37◦C. 
 
4.6 In vitro release profile 
From the in vitro release profile shown in Figure 4.7, it can be observed that the rate 
of release of IOs from the IO loaded PLGA-mPEG nanoparticles for the first 4 days 
was pretty constant, and then it increased a little (from day 5 to 6) before slowing 
down again. At the end of 9 days, about 20% of IOs were released. Subsequently, 
there was very little IOs release. In fact after 31 days, only 21.3% (SD = 1.8%) of IOs 
were released (Data is not shown in Figure 4.7). Hence, it can be deduced that iron 
leakage from the IO loaded PLGA-mPEG nanoparticles was very slow. Since the 
nanoparticles were non-toxic, they hold the potential to be used for prolonging MR 
imaging provided that the nanoparticles were not cleared from the body during the 
scan time.  
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IO loaded PLGA-mPEG nanoparticles 
in vitro release in PBS
 
Figure 4.7 In vitro release profile of the IO loaded PLGA-mPEG nanoparticles 




We have shown that the IOs used for encapsulation are Fe3O4 through XRD and XPS. 
The IO loaded PLGA-mPEG nanoparticles are 233 ± 12.5 nm in diameter, have 
negative surface charge, and their Fe loading is about 1.37%. Successful 
encapsulation of the IOs inside the PLGA-mPEG matrix is verified by TEM and XPS. 
Through FESEM pictures, we can observe that the IO loaded PLGA-mPEG 
nanoparticles are spherical. It is also demonstrated that the IO loaded PLGA-mPEG 
nanoparticles are stable with little changes in size and insignificant amount of iron 
leakage after proplonged exposure to osmotic NaCl solution. Only a small amount of 
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 IOs were released from the IO loaded PLGA-mPEG nanoparticles after 31 days. So 
far, the IO loaded PLGA-mPEG nanoparticles have exhibited physicochemical 
properties suitable for MRI applications. 
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 Chapter 5 Magnetization properties 
 
The aim of this part of the project is to investigate the magnetic properties of the IOs 
and IO loaded PLGA-mPEG nanoparticles so as to access their feasibility as contrast 
agent for MRI and their efficacy as compared to the IOs that are currently being used. 
 
5.1 Characteristics of superparamagnetic materials  
 
To obtain more information regarding the magnetic properties of the IOs and IO 
loaded PLGA-mPEG nanoparticles, the field dependence of the magnetization at a 
constant temperature, and specifically, the characteristics of the hysteresis cycle are 
evaluated. This is shown in Figure 5.1 for both IOs and IO loaded PLGA-mPEG 
nanoparticles. It can be observed that the two types of material generally display 
similar magnetic behaviour. They show characteristic of superparamagnetic particles 
with zero hysteresis cycle, and no coercive field and remanent magnetization. 























 IO loaded PLGA-mPEG nanoparticles
 IOs
Hysteresis loops at 300K
 
Figure 5.1 Magnetization curve for IOs and IO loaded PLGA-mPEG 
nanoparticles at 300K. 
 
5.2 Magnetization – temperature dependence  
 
Figure 5.2 illustrates the influence of temperature on the magnetization for IOs for an 
applied field 20 kOe. Basically, a parabolic decrease of magnetization with 
temperature is observed. This is because as temperature rises, the increase in thermal 
motion interferes with the order produced by the molecular field which is responsible 
for the parallel orientation of the magnetic moments of a domain [13]. Figure 5.2 also 
reveals that the differences in magnetization between IOs and IO loaded PLGA-
mPEG nanoparticles became greater as the temperature increased. At 300 K, the 
saturation magnetization of IO loaded PLGA-mPEG nanoparticles was 83.5 emu/g 
while that of IOs was 72.9 emu/g.  
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It is known that magnetization of the IOs is directly correlated to their size: the larger 
the size the stronger the magnetization [59]. This could be the possible reason for the 
increased Ms of the IOs after encapsulation in this study, as IO agglomeration might 
occur during the formulation process. Actually, change of magnetic properties of the 
IOs after polymer encapsulation has been reported previously, but a decreased Ms 
was observed [13]. This could be due to the encapsulation of a single magnetic 
nucleus instead of a cluster of IOs, as TEM images taken showed a single iron core in 
the polymer matrix.  
 


























 IO loaded PLGA-mPEG nanoparticles
 
Figure 5.2 Magnetization as a function of temperature for the IOs and the IO 




 5.3 Blocking temperature TB
 
The divergence between the susceptibility in a ZFC process and in a FC process is 
another typical feature of superparamagnetic materials. It arises from the anisotropy 
barrier blocking of the magnetization orientation in the nanoparticles cooled with a 
ZFC process [60], thus demonstrating that superparamagnetism is indeed preserved 
after encapsulation. It can be observed in Figure 5.3 that as temperature increases, the 
ZFC magnetization increases and reaches a peak, where the temperature is known as 
TB. This is defined as the temperature at which the nanoparticle moments do not relax 
during the time scale of the measurement [59]. It is an important parameter in the 
study of a magnetic particle system as the IOs would exhibit superparamagnetic 
properties above TB [61]. 
 
Below TB, there is random orientation of the easy axes among the nanoparticles, the 
net susceptibility can be taken to be zero as the applied field is too small to overcome 
the magnetic anisotropy. Above TB, there is sufficient thermal energy to overcome the 
anisotropy and the nanoparticles are aligned according to the applied field. Therefore, 
TB marks the transition between the ferromagnetic and superparamagnetic states. 
After encapsulation, the blocking temperature had increased from 187 K to 212 K. It 
is known that the blocking temperature increases with IO particle size, as a greater 
energy for a larger particle size is required to overcome the anisotropy barrier. Again, 
this implies that there may be an agglomeration of IOs in the PLGA-mPEG matrix 
after encapsulation.  
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Figure 5.3 Blocking temperatures of (a) IO and (b) IO loaded PLGA-mPEG 
nanoparticles. 
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 5.4 Summary  
 
From the above experimental results, it can be seen that both the IOs and IO loaded 
PLGA-mPEG nanoparticles exhibit superparamagnetic behaviours. In addition, the 
IO loaded PLGA-mPEG nanoparticles have larger saturation magnetization and 
higher blocking temperature than the IOs. Both phenomena are known to occur when 
there is an increase in size of IOs, thus this can imply that there is an agglomeration 
of IOs inside the polymer matrix. Regardless of the mechanism behind the changes 
observed, incorporations of IOs into PLGA-mPEG nanoparticles have indeed altered 
the magnetization of the IOs, this may in turn affect the MR contrast effects of the IO 






 Chapter 6 In vitro MR studies 
 
Since the magnetization measurements have shown that the IO loaded PLGA-mPEG 
nanoparticles had greater saturation magnetization than the commercial IOs, it 
warrants MRI experiments to be carried out to assess if this enhancement in 
magnetization can be correlated with higher MR relaxivities. 
 
6.1 Relaxivity plots 
 
To obtain the r1, r2 and r2* relaxivities of the nanoparticles using MRI, images have 
to be taken over a range of TR and TE values. The relaxivity plots of IOs, and IO 
loaded PLGA-mPEG nanoparticles are presented in Figure 6.1 and the summary of 
their relaxivities are summarised in Table 6.1. There was little change observed with 
r1. However, the IO loaded PLGA-mPEG nanoparticles developed were about twice 
more efficient than the IOs based on their in vitro r2 and r2* data.  
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Table 6.1 r1, r2 and r2* relaxivities of the IOs and the IO loaded PLGA-mPEG 
nanoparticles. 
 
Sample r1 ( 1 1mM s− −⋅ ) r2 ( 1 1mM s− −⋅ ) r2* ( ) 1 1mM s− −⋅
IOs  11.4  282.4  266.5 
IO loaded PLGA-mPEG 
nanoparticles 






 6.2 Qualitative analysis 
 
For qualitative analysis, a comparison of in vitro MR images of the IOs and IO loaded 
PLGA-mPEG nanoparticles suspended in water was conducted. From Figure 6.2, it 
can be observed that at TE=7 ms the IO loaded PLGA-mPEG nanoparticles produced 
darker images for all different concentrations of iron. This demonstrates that our IO 
loaded PLGA-mPEG nanoparticles could achieve greater a contrast effect than 
commercial IOs. Previously, Kim et al [62] had conducted in vitro MRI imaging of 










6.3 Investigations on encapsulation effects 
 
To further verify the effect of IO particle encapsulation on r2 and r2* relaxivity, MRI 
was carried out on blank PLGA-mPEG nanoparticles, IOs and mixtures of IOs with 
different concentrations of blank PLGA-mPEG nanoparticles. Figure 6.3 shows that 
blank PLGA-mPEG nanoparticles do not enhance the proton relaxation rate as their 
relaxation rates for different concentration are almost constant. In addition, the 
mixtures of blank PLGA-mPEG nanoparticles with 0.2 mM IOs had no effect on r2 
and r2* relaxivities of IOs. Their relaxation rates were similar to that of 0.2mM IOs. 
This result confirms that it is the encapsulation of IOs with PLGA-mPEG that leads to 
the contrast enhancement, and pure physical mixing of IOs with blank nanoparticles 
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Figure 6.3 Relaxation rate (a) R2 and (b) R2* of blank PLGA-mPEG 




 6.4 Theories behind relaxivity enhancement  
 
As mentioned earlier, the R2 relaxation rates increases with particle sizes in the 
motional averaging regime and the maximum R2 relaxation rate is achieved in SDR. 
Thus, it can be deduced that both the IOs and IO loaded PLGA-mPEG nanoparticles 
are either in the MAR or SDR. Gillis et al has reported that the maximum R2* 
relaxation rate that can be achieved by IOs when simulated at equatorial field of 1 kG 
( ) and volume fraction of  is equal to 160 ssradr /1036.2
7×=∆ω 6105 −×=v -1 [36]. 
Making use of their simulated results, we can estimate the maximum R2* relaxation 
rate for IOs which is actually magnetite. Given the magnetite volumic mass 
(5100kg/m3) and its chemical composition (Fe3O4), the volume fraction of magnetite 
for 1mM of iron is . By substituting  and 
 (equatorial field of magnetite is 1.3 kG) into (5), the 
maximum R
6102.15 −×=v 61052.1 −×=v
sradr /1007.3
7×=∆ω
2* relaxation rate is approximately 630 s-1. Since relaxivity is defined as 
the relaxation rate for 1mM of iron, the maximum r2* relaxivity is 630 . The 
r
1mM s− −⋅ 1
2* relaxivity achieved by our IO loaded PLGA-mPEG nanoparticles falls within this 
upper theoretical bound, thus proving that our results is reasonable. A similar work 
carried out by Pouliquen et al [18] had reported a decrease MR relaxivities after 
encapsulation. Since they did not carry out any r2* measurements, one explanation 
could be that their results were not accounted for by the MAR or SDR. Another 
possible reason for the decreased relaxivities could be due to the increased distance 
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 between the IOs in the polymer matrix and the water molecules at the surface of the 




There are several prominent phenomenons that are observed. Firstly, the r2 and r2* 
relaxivities of the IO loaded PLGA-mPEG nanoparticles approximately doubled 
those of the IOs after encapsulation. Secondly, the r2 and r2* relaxivities of IO loaded 
PLGA-mPEG nanoparticles could be considered as equal. Last but not least, the MR 
images have also proved that with the same concentration of iron present, the IO 
loaded PLGA-mPEG nanoparticles gave darker images. Therefore, the IO loaded 
PLGA-mPEG nanoparticles show great potential to serve as a better contrast agent for 
clinical MR imaging. 
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 Chapter 7 Animal studies 
 
The desirable R2 and R2*-relaxation enhancing properties of the IO loaded PLGA-
mPEG nanoparticles warrant animal studies of their efficacy as a MRI contrast agent. 
However, before doing that, it will be useful to know the biodistribution of the 
injected IOs and IO loaded PLGA-mPEG nanoparticles. The biodistribution data can 
provide an idea of specificity to the organ sites to be used for achieving the best MR 
image. In addition, the results obtained can be used to investigate the effects of 
encapsulation of IOs on the biodistribution. In this section, the results of the 
biodistribution and ex vivo MRI are presented and discussed. 
 
7.1 Biodistribution studies 
 
The distribution of iron in the various organs (heart, kidney, liver, spleen and brain) 
of the rats (control, IOs, and IO loaded PLGA-mPEG nanoparticles) was shown in 
Figure 7.1. From the graph, it can be observed that most of the IOs and IO loaded 
PLGA-mPEG nanoparticles were found in the liver. This is expected because 
majority of particles injected intravenously are lost to the reticulo-endothelial system 
(RES), they are taken up mainly by macrophages in the liver after opsonization by 
proteins in the bloodstream. The degree of opsonization depends on the size and 
surface properties of particles. The liver and spleen usually take up particles between 
50-500 nm which coincide with the size of the IOs and IO loaded PLGA-mPEG 
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 nanoparticles. This natural tendency enables passive targeting to RES. Thus to avoid 
targeting to RES, particles have to overcome opsonization and thus uptake by RES. 
For effective targeting to other organs, ligands such as folate [48] and lectins [49] 
may have to be attached to the surface of the nanoparticles.   
 
 
Figure 7.1 Biodistribution of iron in various organs (1 hr after injection) 
 
 
7.2 Ex vivo MRI 
 
The IO loaded PLGA-mPEG nanoparticles were injected into the tail vein of male 
Sprague Dawley rats. The liver of the rat injected with IO loaded PLGA-mPEG 
nanoparticles in Figure 7.2 was shown darker compared to the control, thus 
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 demonstrating the efficacy of these nanoparticles in enhancing the in vivo proton 
relaxation rate. Ferrofluid encapsulated PLGA particles had been investigated as a 
MRI contrast agent in the kidney of rabbit by other researchers, and the enhanced 
contrast of MRI image was reported after the injection of the composite nanoparticles 
[2]. 
 
Figure 7.2 MR imaging of the livers of the rats (upper is the control; bottom is 




The biodistribution shows that the distribution of IO loaded PLGA-mPEG 
nanoparticles does not differ from that of the IOs. Both of them were found to 
accumulate in the liver which is expected as the liver is responsible for removal of 
foreign particles in the body. In order to evade the RES and reach the other organs 
like the brain, the IOs and IO loaded PLGA-mPEG nanoparticles may require surface 
modification and/or size reduction for successful penetration of the blood-brain 
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 barrier. The ex vivo MR image of the rats’ livers demonstrates that the IO loaded 
PLGA-mPEG nanoparticles were indeed effective at reducing the signal intensity and 
produce darker image. Therefore, they can be used as MRI contrast agents. 
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In this project, IO loaded PLGA-mPEG nanoparticles were developed for use in MRI 
as an alterative to IOs because there is a need to develop special contrast agents that 
increase the MRI signal intensity for future applications such as imaging of specific 
molecular targets to allow for earlier recognition and characterization of disease, 
earlier and direct evaluation of treatment outcomes, and a deeper understanding of 
disease development. 
 
After thorough examinations of the physical and chemical properties, the IOs are 
found to be Fe3O4, the iron cores were about 5 nm as seen in TEM picture and the 
overall size (including the dextran coating) was about 60 nm. While the IO loaded 
PLGA-mPEG nanoparticles were approximately 233 nm, spherical, and negatively 
charged. They also exhibited size and storage stability as there was negligible 
changes in size and insignificant amount of iron leakage from the nanoparticles after 
48 hours of exposure to osmotic agent NaCl. Only a small amount of IOs released 
from the IO loaded PLGA-mPEG nanoparticles even after 31 days. Thus, the 




 Investigations of the magnetic properties of the IOs and IO loaded PLGA-mPEG 
nanoparticles show that both the IOs and IO loaded PLGA-mPEG nanoparticles 
display superparamagnetic property such as zero hysteresis loops above blocking 
temperature. It is also observed that after encapsulation, Ms increased from 72.9 
emu/g to 83.5 emu/g at 300 K and TB increased from 187 K to 212 K. This results is 
in agreement with the report in the literature [59, 61]. Therefore, the increased 
saturation magnetization and blocking temperature of IO loaded PLGA-mPEG 
nanoparticles can be due to agglomeration of IOs inside the polymer matrix.  
 
Since the objective is to develop the IO loaded PLGA-mPEG nanoparticles as MR 
contrast agents, it is important to assess their MR properties. Relaxivity of a contrast 
agent is the key factor in evaluating its effectiveness, therefore in vitro MR studies 
were conducted to determine the r1, r2 and r2* relaxivities of the IOs and IO loaded 
PLGA-mPEG nanoparticles. After encapsulation, there was insignificant change in r1 
relaxivity while r2 relaxivity increased from 282.4  to 532.7  and 
the r
11 −− smM 11 −− smM
2* relaxivity increased from 266.5  to 537.5 .  IOs act as 
contrast agents in MRI by decreasing the signal intensity of images, hence only the r
11 −− smM 11 −− smM
2 
and r2* relaxivities are of importance. Since the r2 and r2* relaxivities almost doubled 
after encapsulation and in vitro MR images of IO loaded PLGA-mPEG nanoparticles 
were darker than that IOs, it can be said that the IO loaded PLGA-mPEG 
nanoparticles were more effective as MR contrast agent than the IOs. The increase in 
relaxivities may be explained by the MAR and SDR. Within the MAR, the relaxivity 
increases as size of IOs increases up to a maximum. The maximum relaxivity is 
 61
 determined by the SDR. From theoretical calculation, the maximum relaxivity for IOs 
which is around 630  has not been reached, thus the increase in relaxivity 
after encapsulation is reasonable. 
11 −− smM
 
As in vitro results may not truly reflect the situations when used in animals, it is 
necessary to conduct animal experiments to show that the IO loaded PLGA-mPEG 
nanoparticles can act as effective MR contrast agents in animals. Prior to ex vivo 
imaging, biodistribution data was collected to determine the amount of IOs and IO 
loaded PLGA-mPEG nanoparticles accumulated in some of the major organs (heart, 
kidney, liver, spleen and brain). The results showed that the IOs and IO loaded 
PLGA-mPEG nanoparticles were found in the kidney, liver and spleen. In fact, liver 
had the highest concentration of both agents. This is expected because the 
macrophages in the liver are known to ingest particles of sizes 50 to 500 nm. The 
particles were practically not existing in the heart and brain. The ex vivo MR image 
of rats’ liver illustrated that the IO loaded PLGA-mPEG nanoparticles could produce 
a darker image of the liver.  
 
In conclusion, the objective of this project has been met since encapsulation had 
increased the relaxation rates of the IOs, making the IO loaded PLGA-mPEG 








What has been done so far is just the foundation; there are several ways in each this 
project can be taken further in order to achieve better results. In this section, I shall 
give some suggestions on further developments.  
1. Dynamic MRI may be carried out to determine how long the IO loaded PLGA-
mPEG nanoparticles stay in the body before they are excreted. 
2. Surface of the nanoparticles can be modified to cross physiological barrier like the 
BBB so that images of other organs like the brain may be able to be imaged by 
MRI. To allow MR imaging of the brain, the surface of the nanoparticles may be 
coated with surfactant like tween 80 which can aid in penetrating the blood-brain 
barrier. The size of nanoparticles may have to be reduced by modifying the 
encapsulation method.  
3. It may be desirable to develop uncoated IOs which have higher saturation 
magnetization than Resovist® so as to further amplify the MRI signal.  
4. Ligands may be attached to the surface of nanoparticles to allow active targeting. 
An example will be attaching folate ligands so that the nanoparticles can be 
specifically targeted to cells like breast tumor cells where folate receptors are 
found in high concentrations.  
5. Drugs may be incorporated into the polymer matrix so that the nanoparticles can 
act as both a therapeutic and diagnostic agent.   
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